Leaderboards/lung cancer treatments and mutations

lung cancer treatments and mutations

Last updated June 2, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Anwen Xiong
Tongji University
90
2
Caicun Zhou
Tongji University
80
3
Jacob Sands
Dana-Farber Cancer Institute
50
4
Caicun Zhou
Tongji University
40
5
S.-H. Lee
Samsung Medical Center
10

Rising Stars Papers

1
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment
Experimental Hematology and Oncology|2024
29 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Matthew Holderfield
Revolution Medicines (United States)
99
2
David Planchard
Harbin Medical University
60
3
C. Jillian Tsai
University Health Network
50
4
Tony Mok
Chinese University of Hong Kong
40
5
Xinyuan Tong
Chinese Academy of Sciences
30
6
Adam J. Schoenfeld
Cornell University
20

Emerging Leaders Papers

1
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Nature|2024
306 cit.

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Matthew Meyerson
Broad Institute
99
2
Timothy A. Chan
Memorial Sloan Kettering Cancer Center
90
3
Luis Paz‐Ares
Hospital Universitario Virgen del Rocío
80
4
Pasi A. Jänne
Shikoku Cancer Center
70
5
Changxuan You
Nanfang Hospital
60
6
Julie R. Brahmer
Sidney Kimmel Comprehensive Cancer Center
50
7
Solange Peters
University Hospital of Lausanne
40
8
Masahiro Fukuoka
Izumi City General Hospital
30
9
Richard K. Wilson
Washington University in St. Louis
20
10
Marina Chiara Garassino
Fondazione IRCCS Istituto Nazionale dei Tumori
10

All-Time Leaders Papers

1
Lung cancer: current therapies and new targeted treatments
The Lancet|2016
3.3k cit.
2
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Annals of Oncology|2018
2.9k cit.
3
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Nature|2008
1.4k cit.
4
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Journal of Clinical Oncology|2015
1.2k cit.
5
Characterizing the cancer genome in lung adenocarcinoma
Nature|2007
1.1k cit.
6
Kinase drug discovery 20 years after imatinib: progress and future directions
Nature Reviews Drug Discovery|2021
1k cit.
7
Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
New England Journal of Medicine|2021
949 cit.
8
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Journal for ImmunoTherapy of Cancer|2021
804 cit.
9
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
PLoS Medicine|2005
683 cit.
10
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
PLoS ONE|2011
369 cit.

Reagents for lung cancer treatments and mutations

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

Promega

VEGF Bioassay

Cited in 36 papers
#G719A
View Evidence →

⭐ Recommended

Best all-around

Cell Signaling Technology

SynGAP (D88G1) Rabbit Monoclonal Antibody

Cited in 30 papers
#9479$161
View Evidence →Cell Signaling Technology

Phospho-Rev-erb alpha (Ser55/59) Antibody

Cited in 25 papers
#2129$362
View Evidence →Cell Signaling Technology

XPC (D1M5Y) Rabbit Monoclonal Antibody

Cited in 24 papers
#14768$161
View Evidence →

🌟 All-Time

Most validated

Promega

VEGF Bioassay

Cited in 36 papers
#G719A
View Evidence →Cell Signaling Technology

ZHX2 Antibody

Cited in 35 papers
#20937$317
View Evidence →Cell Signaling Technology

COL3A1 Antibody

Cited in 30 papers
#30565$317
View Evidence →